| 05/20 | Regeneron, Sanofi Receive US FDA Approval of Dupixent for Eosinophilic Esophagitis | MT |
| 05/20 | Sanofi's Dupixent wins U.S. approval for bigger use | RE |
| 05/20 | FDA Grants Regeneron Approval for Dupixent in Inflammatory Disorder Treatment | DJ |
| 05/20 | EU Member States Seek Changes To Supply Contracts For COVID-19 Jabs Amid Declining Dema.. | MT |
| 05/19 | US Health Agency Approves Pfizer-BioNTech's COVID-19 Booster Jab For Children | MT |
| 05/19 | EU health regulator backs using AstraZeneca COVID shot as booster | RE |
| 05/19 | European ADRs Move Higher in Thursday Trading | MT |
| 05/19 | Junshi's COVID-19 Drug Candidate Shows Positive Results in Small Trial; Shares Jump Nea.. | MT |
| 05/18 | Vertex Pharmaceuticals Incorporated Elects Suketu Upadhyay as Independent Director | CI |
| 05/18 | China Junshi's potential COVID drug shows promise in small trial | RE |
| 05/17 | Pfizer-BioNTech COVID-19 Vaccine Booster Approved for Children 5 to 11 Years Old in US | MT |
| 05/17 | UBS Adjusts BioNTech Price Target to $168 From $170, Maintains Neutral Rating | MT |
| 05/17 | Pfizer, BioNTech Receive US Approval for COVID-19 Jab Booster Dose for Children | MT |
| 05/17 | Pfizer Gets FDA Emergency Use Authorization for COVID-19 Vaccine as Booster Dose in Chi.. | MT |
| 05/17 | FDA Expands Authorization of Pfizer Covid Booster to Kids 5 to 11 | DJ |
| 05/17 | PRESS RELEASE : Coronavirus (COVID-19) Update: FDA Expands Eligibility for Pfizer-BioNTech.. | DJ |
| 05/17 | Vertex Pharmaceuticals Pledges $50 Million to Health Equity | MT |
| 05/17 | Vertex Pharmaceuticals Incorporated Announces Further Expansion in the Boston Seaport A.. | CI |
| 05/17 | ANALYST RECOMMENDATIONS : AMD, CarMax, Gilead, J.B. Hunt, Vodafone... | |
| 05/17 | Piper Sandler Adjusts Gilead Sciences' Price Target to $69 From $73, Maintains Neutral .. | MT |
| 05/17 | WuXi Apptec Eyes Issue of Over 78 Million Shares in Hong Kong Under Mandate | MT |
| 05/16 | Gilead Sciences Says FDA Lifts Hold on Investigational Lenacapavir to Treat HIV | MT |
| 05/16 | U.S. Food and Drug Administration Lifts Clinical Hold on Investigational Lenacapavir fo.. | CI |
| 05/16 | Gilead Sciences Says FDA Lifts Clinical Hold On Injectable Lenacapavir | DJ |
| 05/16 | European ADRs Move Higher in Monday Trading | MT |
| 05/15 | Pfizer, BioNTech Agree To Move Delivery Schedules For COVID-19 Vaccines In EU | MT |
| 05/13 | UBS Adjusts Gilead Sciences Price Target to $64 From $65, Maintains Neutral Rating | MT |
| 05/11 | New class of cancer drugs down, not out, after Roche trial setback - analysts | RE |
| 05/11 | Pfizer's $11.6 billion Biohaven buy could spark more biotech deals | RE |
| 05/11 | European ADRs Move Sharply Higher in Wednesday Trading | MT |
| 05/11 | BIONTECH : Goldman Sachs sticks Neutral | MD |
| 05/10 | TRANSCRIPT : Gilead Sciences, Inc. Presents at Bank of America 2022 Healthcare Conference,.. | CI |
| 05/10 | TRANSCRIPT : Regeneron Pharmaceuticals, Inc. Presents at Bank of America 2022 Healthcare C.. | CI |
| 05/10 | Morgan Stanley Lowers BioNTech SE's Price Target to $195 From $197, Equalweight Rating .. | MT |
| 05/10 | What you need to know about the coronavirus right now | RE |
| 05/09 | BIONTECH : JP Morgan reiterates its Neutral rating | MD |
| 05/09 | SECTOR UPDATE : Health Care Stocks Declining Ahead of Monday Close | MT |
| 05/09 | SECTOR UPDATE : Health Care Stocks Slide with Broader Monday Markets | MT |
| 05/09 | BioNTech Q1 Results Top Street Estimates; Shares Gain | MT |
| 05/09 | UBS Adjusts Vertex Pharmaceuticals Price Target to $321 From $322, Maintains Buy Rating | MT |
| 05/09 | BIONTECH : Jefferies reiterates its Neutral rating | MD |
| 05/09 | BioNTech Q1 Earnings, Revenue Surge; Shares Rise Pre-Bell | MT |
| 05/09 | TRANSCRIPT : BioNTech SE, Q1 2022 Earnings Call, May 09, 2022 | CI |
| 05/09 | Equities Slide Pre-Bell as US Signals More Losses; Europe, Asia Retreat | MT |
| 05/09 | Wall Street Leans Back Pre-Bell; Europe Off, Asia Down | MT |
| 05/09 | BioNTech Reiterates 2022 Vaccine Revenue Guidance After Boost In Q1 Earnings | MT |
| 05/09 | COVID vaccine makers shift focus to boosters | RE |
| 05/09 | Earnings Flash (BNTX) BIONTECH SE Posts Q1 EPS EUR14.24 | MT |
| 05/09 | Earnings Flash (BNTX) BIONTECH SE Posts Q1 Revenue EUR6.38B | MT |
| 05/09 | BioNTech SE Reports Earnings Results for the First Quarter Ended March 31, 2022 | CI |
English (UK)
English (Canada)
Deutsch (Deutschland)
Deutsch (Schweiz)
Español
Français (France)
Italiano
Nederlands (Nederland)
Nederlands (België)
Report
